Chloroquine (DB00608): A Comprehensive Pharmacological and Clinical Monograph

Executive Summary

Chloroquine is a synthetic 4-aminoquinoline derivative that has occupied a multifaceted and often paradoxical role in medicine for over 70 years. Initially developed in the 1930s and widely adopted after World War II, it became a cornerstone of global malaria prophylaxis and treatment due to its high efficacy, low cost, and convenient dosing. However, its dominance was curtailed by the inexorable spread of parasite resistance, which has rendered it largely ineffective against the most lethal malaria parasite, Plasmodium falciparum, in most parts of the world. Serendipitous clinical observations during its widespread use led to its repurposing as a disease-modifying antirheumatic drug (DMARD). Today, its most significant clinical applications are in the management of autoimmune conditions such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), where it exerts immunomodulatory effects by interfering with antigen presentation and inflammatory signaling. This therapeutic utility is tempered by a significant safety profile, characterized by the risk of irreversible retinopathy and potentially fatal cardiotoxicity, particularly with the long-term, high-dose regimens required for autoimmune diseases. The recent, intense but ultimately unsuccessful investigation of Chloroquine for the treatment of COVID-19 served as a modern case study in the complexities of drug repurposing, underscoring the critical need for rigorous clinical evidence to validate preclinical hypotheses. This report provides a comprehensive monograph on Chloroquine, detailing its chemical properties, pharmacological mechanisms, clinical applications, and complex safety considerations.

Chemical Identity and Pharmaceutical Profile

A thorough understanding of Chloroquine's pharmacological behavior begins with its fundamental chemical and physical characteristics.

Nomenclature and Identifiers

Chloroquine is a small molecule drug belonging to the aminoquinoline class.[1] It is identified across scientific and regulatory databases by its DrugBank ID, DB00608, and its Chemical Abstracts Service (CAS) Number, 54-05-7.[1] Its systematic International Union of Pure and Applied Chemistry (IUPAC) name is N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine.[1] The drug is known by numerous synonyms and international names, including Chloraquine, Chlorochin, Chloroquina, and the common brand name Aralen.[1]

Chemical Structure and Formula

The molecular formula of Chloroquine is C18​H26​ClN3​.[1] Structurally, it is a 4-aminoquinoline, composed of a quinoline bicyclic aromatic core that is substituted at position 7 with a chlorine atom and at position 4 with a [5-(diethylamino)pentan-2-yl]amino side chain.[2] This specific arrangement of a lipophilic aromatic ring system and a basic side chain is fundamental to its biological activity. Its structure is precisely defined by identifiers such as the SMILES string CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl.[3]

Physicochemical Properties

Chloroquine is a weak base, a property that is central to its mechanism of action and pharmacokinetic profile.[5] It presents as a white to light yellow crystalline solid with a bitter taste.[3] Its physicochemical properties are summarized in Table 1.

Table 1: Chemical and Physical Properties of Chloroquine

Property	Value	Source(s)
Generic Name	Chloroquine	1
DrugBank ID	DB00608	1
CAS Number	54-05-7	3
Drug Type	Small Molecule	1
Chemical Class	4-aminoquinoline	6
Molecular Formula	C18​H26​ClN3​	1
Average Molecular Weight	319.872 g/mol	1
IUPAC Name	N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine	1
Physical Appearance	White to light yellow solid	3
Melting Point	87°C	3
XLogP	4.27	4
pKa (Strongest Basic)	10.32	9

The physicochemical nature of Chloroquine is the primary determinant of its biological fate and action. Its lipophilic quinoline ring structure allows it to readily diffuse across biological membranes, including the membranes of host red blood cells and the intraerythrocytic malaria parasite.[6] Once inside the cell, its character as a weak base becomes paramount. The drug has a pKa of 8.5 for its quinoline nitrogen, meaning it is largely protonated at physiological pH.[6] However, when it enters highly acidic intracellular compartments—such as the parasite's food vacuole (pH ≈ 4.7) or a host cell's lysosome (pH ≈ 4.6)—the equilibrium shifts dramatically, and the drug becomes almost entirely protonated.[6] This charged, protonated form is significantly less membrane-permeable, effectively trapping the molecule within the acidic organelle. This phenomenon, known as "ion trapping," leads to a massive accumulation of Chloroquine in these specific compartments.[6] This accumulation is not a side effect but the very basis of its therapeutic activity, concentrating the drug at its site of antimalarial action and simultaneously enabling its immunomodulatory effects by altering the internal environment of host immune cells.

Pharmaceutical Formulations

For clinical use, Chloroquine is typically formulated as a salt, most commonly chloroquine phosphate or chloroquine sulfate, for oral administration in tablet form.[8] It is critical to distinguish between the weight of the salt and the weight of the active Chloroquine base for accurate dosing. For instance, a 250 mg tablet of chloroquine phosphate is equivalent to 150 mg of Chloroquine base, while a 500 mg tablet contains 300 mg of base.[14]

Historical Development and Evolving Role in Medicine

The history of Chloroquine is a compelling narrative of 20th-century pharmaceutical development, marked by wartime necessity, serendipitous clinical observation, and the persistent challenge of microbial evolution.

Origins and Discovery

The story begins with the natural antimalarial quinine, isolated from the bark of the South American Cinchona tree in the 19th century.[5] The quest for more reliable and scalable synthetic alternatives drove research in the early 20th century. This effort culminated in 1934 when Hans Andersag, working at the Bayer laboratories in Germany, first synthesized the 4-aminoquinoline compound he named Resochin.[6] However, initial assessments deemed the compound too toxic for human use, and it was consequently shelved for nearly a decade.[19]

World War II and Clinical Adoption

The trajectory of the drug was irrevocably altered by the events of World War II. The need for effective antimalarials to protect Allied troops was a strategic imperative. A related formulation, sontoquine, was captured from German forces in North Africa and subsequently analyzed by American researchers.[19] This prompted a re-evaluation of the original compound, Resochin, which was found to be both safe and highly effective. Renamed Chloroquine, it underwent extensive clinical trials and was granted FDA approval on October 31, 1949, becoming commercially available shortly thereafter.[1]

The "Golden Age" and Repurposing

In the post-war era, Chloroquine became the global drug of choice for both the treatment and prophylaxis of malaria, playing a central role in the World Health Organization's ambitious malaria eradication campaign.[1] During this period of widespread use, a pivotal, serendipitous discovery was made. Soldiers taking the drug for malaria prophylaxis reported unexpected improvements in concurrent inflammatory conditions, such as skin rashes and arthritis.[11] These astute clinical observations led to formal trials in the 1950s, which confirmed its efficacy in autoimmune diseases like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), establishing its second major therapeutic role.[1]

Development of Hydroxychloroquine

In response to concerns about Chloroquine's long-term toxicity, particularly to the retina, a hydroxylated analogue, hydroxychloroquine, was developed and introduced in 1955.[11] This derivative offered a similar therapeutic profile but with a significantly better safety record, and it has since largely superseded Chloroquine for the chronic treatment of autoimmune diseases.[14]

The Rise of Resistance and Modern Status

Chloroquine's "golden age" as the premier antimalarial was ultimately brought to an end by the predictable evolutionary response of its target. Widespread resistance in P. falciparum was first documented in the late 1950s and spread globally over the subsequent decades, severely limiting its utility.[1] This crisis spurred the development of newer antimalarials, including mefloquine and the now-standard artemisinin-based combination therapies (ACTs).[1] Despite the challenge of resistance, Chloroquine's importance is recognized by its continued inclusion on the World Health Organization's List of Essential Medicines for its remaining indications.[4]

In-Depth Pharmacology: Mechanisms of Action

Chloroquine exhibits distinct mechanisms of action in its different therapeutic contexts. However, these diverse effects are all downstream consequences of a single, unifying pharmacological principle: its accumulation within acidic intracellular organelles, a property known as lysosomotropism.

The Antimalarial Mechanism: Heme Polymerase Inhibition and Lysosomal Disruption

The antimalarial action of Chloroquine targets a critical metabolic process of the Plasmodium parasite during its asexual lifecycle stage within human red blood cells.[6]

1. Heme Detoxification Pathway: The parasite resides within an acidic digestive vacuole (pH ≈ 4.7), where it degrades large quantities of host hemoglobin to acquire essential amino acids for its own protein synthesis.[6] This digestion process liberates vast amounts of heme (ferriprotoporphyrin IX), a molecule that is highly toxic to the parasite due to its ability to generate reactive oxygen species and disrupt membranes.[6] To survive, the parasite has evolved a detoxification mechanism: it biocrystallizes the toxic heme into a non-toxic, insoluble polymer called hemozoin. This polymerization is catalyzed by an enzyme known as heme polymerase.[1]
2. Chloroquine's Intervention: Due to the ion-trapping phenomenon described previously, Chloroquine accumulates to millimolar concentrations within the parasite's acidic food vacuole.[6] At this high concentration, it acts through a dual mechanism. First, it directly inhibits the action of heme polymerase, preventing the conversion of heme to hemozoin.[1] Second, it binds with high affinity to heme molecules, forming a toxic heme-chloroquine complex and physically "capping" the growing hemozoin polymer chains, which halts further crystallization.[6]
3. Parasite Death: The result is a rapid buildup of toxic free heme and heme-chloroquine complexes within the parasite. This accumulation leads to oxidative stress, membrane damage, and ultimately, lysis and autodigestion of the parasite.[1]

The Immunomodulatory Mechanism: Antigen Presentation and Cytokine Suppression in Autoimmune Disease

In autoimmune diseases like SLE and RA, Chloroquine's therapeutic effect stems from its interference with the cellular processes that drive the aberrant immune response. This mechanism is also a direct result of its lysosomotropic properties, but in this case, the target is the host's own immune cells.[12]

1. Alkalinization of Lysosomes: Chloroquine accumulates in the acidic lysosomes and endosomes of antigen-presenting cells (APCs), such as macrophages and dendritic cells.[12] This accumulation raises the internal pH of these organelles from approximately 4.5 to around 6.0.[11]
2. Inhibition of Antigen Processing: The enzymes within lysosomes (acid hydrolases) that are responsible for breaking down proteins into smaller peptides for antigen presentation are highly pH-dependent and function optimally in an acidic environment. The Chloroquine-induced alkalinization inhibits these enzymes, impairing the processing of autoantigens.[12]
3. Disruption of MHC Class II Loading: The subsequent step, the loading of these antigenic peptides onto Major Histocompatibility Complex (MHC) class II molecules, is also a pH-dependent process. By disrupting this critical step, Chloroquine diminishes the formation and surface expression of the peptide-MHC class II complexes that are required to activate autoreactive CD4+ T cells. This effectively down-regulates the autoimmune response at a key initiation point.[29]
4. Inhibition of Toll-Like Receptors (TLRs): A significant secondary mechanism, particularly relevant in SLE, is the inhibition of endosomal TLRs. TLR7 and TLR9, which recognize self-derived nucleic acids and drive the production of pro-inflammatory type I interferons, are located within endosomes. By raising the endosomal pH and possibly interfering with nucleic acid binding, Chloroquine blunts this critical inflammatory signaling pathway, reducing cytokine production.[11]

Ancillary Mechanisms: Antiviral and Other Cellular Effects

The same fundamental properties of Chloroquine have led to investigations of its antiviral activity. The ability to raise the pH within endosomes can interfere with the entry of many viruses that rely on a low pH environment to trigger the fusion of their envelope with the endosomal membrane.[1] Specifically for SARS-CoV-2, it was also proposed that Chloroquine could inhibit the terminal glycosylation of the Angiotensin-Converting Enzyme 2 (ACE2) receptor, potentially reducing the binding efficiency of the viral spike protein.[1] While these mechanisms provided a plausible

in vitro rationale for its use in COVID-19, they failed to translate into clinical benefit. Large-scale clinical trials found no evidence of efficacy and suggested potential harm, leading the U.S. Food and Drug Administration (FDA) to revoke its Emergency Use Authorization (EUA) on June 15, 2020.[1]

Clinical Pharmacokinetics: A Profile of Absorption, Distribution, Metabolism, and Excretion (ADME)

The clinical use and toxicity profile of Chloroquine are governed by its unique and extreme pharmacokinetic properties, particularly its vast distribution and slow elimination. A summary of these parameters is provided in Table 2.

Absorption

Following oral administration, Chloroquine is rapidly and almost completely absorbed from the gastrointestinal tract.[5] Its bioavailability is high, though it can be variable, with reported ranges of 52-102% for oral solutions and 67-114% for oral tablets.[1] Peak plasma concentrations are typically reached within 0.5 to 12 hours after a dose, reflecting some inter-individual variability in absorption rates.[1]

Distribution

The distribution of Chloroquine is the most defining feature of its pharmacokinetics. It possesses an exceptionally large apparent volume of distribution (Vd​), reported to be between 200 and 800 L/kg.[1] This value, which vastly exceeds total body water, indicates that the vast majority of the drug in the body is not in the plasma but is extensively sequestered in various tissues.[5] This tissue binding is substantial, with Chloroquine having a particular affinity for melanin-containing cells in the skin and, most critically, the retinal pigment epithelium of the eye.[5] This specific accumulation is directly responsible for the risk of irreversible retinopathy with chronic use. In the plasma, Chloroquine is 46-79% bound to proteins, including albumin and alpha-1-acid glycoprotein.[1]

Metabolism

Chloroquine undergoes partial metabolism in the liver, primarily through N-dealkylation reactions catalyzed by the cytochrome P450 (CYP) enzyme system.[6] The main enzymes responsible for this biotransformation are CYP2C8 and CYP3A4/5, with lesser contributions from CYP2D6 and CYP1A1.[1] The principal metabolite, N-desethylchloroquine, retains some antimalarial activity and can be further dealkylated to inactive metabolites.[1] Notably, Chloroquine itself is an inhibitor of CYP2D6, which creates a potential for drug-drug interactions with other medications metabolized by this pathway.[44]

Excretion

The primary route of elimination for Chloroquine and its metabolites is via the kidneys.[1] A substantial portion of the drug, approximately 50%, is excreted in the urine as the unchanged parent compound, with about 10% excreted as desethylchloroquine.[1] The elimination process is extremely slow, a direct consequence of the extensive tissue sequestration and large volume of distribution. Because only the drug present in the plasma is available for renal clearance, the slow release from tissue reservoirs results in a remarkably long terminal elimination half-life, typically ranging from 20 to 60 days.[1] This protracted elimination means that the drug can be detected in the body for months after discontinuation of therapy.[44]

This extreme pharmacokinetic profile can be viewed as a double-edged sword. The long half-life is highly advantageous for malaria prophylaxis, as it allows for a convenient and effective once-weekly dosing regimen that promotes adherence.[15] However, this same property becomes a significant liability in the context of chronic, daily dosing for autoimmune diseases. The slow elimination and extensive tissue binding lead to progressive drug accumulation over months and years. This cumulative burden, especially in sensitive tissues like the retina and myocardium, is the direct cause of its most severe, irreversible toxicities. Thus, the very characteristic that makes it an excellent prophylactic agent is also what makes it a hazardous long-term therapy, necessitating careful risk management and diligent patient monitoring.

Table 2: Summary of Key Pharmacokinetic Parameters for Chloroquine

Parameter	Value	Source(s)
Bioavailability (Oral)	67–114% (tablets)	1
Tmax​ (Oral)	0.5–12 hours	1
Volume of Distribution (Vd​)	200–800 L/kg	1
Plasma Protein Binding	46–79%	1
Primary Metabolic Pathways	Hepatic N-dealkylation (CYP2C8, CYP3A4/5)	1
Primary Active Metabolite	N-desethylchloroquine	1
Route of Elimination	Renal	1
Percent Excreted Unchanged	~50% in urine	1
Terminal Half-life	20–60 days	1
Total Plasma Clearance	0.35–1 L/h/kg	1

Therapeutic Applications: From Malaria to Autoimmunity

Chloroquine's clinical utility has evolved significantly over time, reflecting both its broad biological activity and the changing landscape of infectious and autoimmune diseases.

Approved Indications: Malaria and Extraintestinal Amebiasis

The primary FDA-approved indications for Chloroquine are rooted in its anti-parasitic activity.[7]

• Malaria: Chloroquine is officially indicated for the treatment and prophylaxis of malaria caused by susceptible strains of Plasmodium vivax, P. malariae, P. ovale, and P. falciparum.[1] However, this indication carries a critical and substantial caveat: the widespread global resistance of P. falciparum and the emergence of resistance in P. vivax mean that its use is now restricted to the few remaining geographic areas where chloroquine-sensitive malaria persists.[6] It is also important to note that Chloroquine is only active against the erythrocytic (blood) stages of the parasite. It is not effective against the dormant liver stages (hypnozoites) of P. vivax and P. ovale, and therefore cannot prevent relapses from these species unless used concomitantly with a drug active against these forms, such as primaquine.[7]
• Extraintestinal Amebiasis: Chloroquine is also approved for the treatment of extraintestinal amebiasis, specifically for liver abscesses caused by the protozoan Entamoeba histolytica.[1]

Repurposed Applications in Rheumatology and Dermatology

The most significant modern use of Chloroquine and its analogue hydroxychloroquine is as a disease-modifying antirheumatic drug (DMARD) for a variety of autoimmune conditions.[1]

• Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA): Though often an off-label use, Chloroquine is a foundational therapy for SLE and a second-line agent for RA. It is particularly effective for managing constitutional symptoms like fatigue and fever, as well as joint pain and skin manifestations.[2] In SLE, it is considered a cornerstone of treatment, with evidence showing that it reduces the frequency of disease flares, prevents the development of organ damage (especially renal disease), and improves long-term survival.[23]
• Other Dermatologic Conditions: Its immunomodulatory and photoprotective effects make it useful for other conditions, including discoid lupus erythematosus, porphyria cutanea tarda, and sarcoidosis.[1]

This evolution has led to a clinical paradox: Chloroquine's primary, original indication for malaria is now largely obsolete in practice due to resistance, while its most important and impactful contemporary uses in rheumatology are often technically off-label and are precisely the applications that carry the highest risk of long-term cumulative toxicity. This highlights a significant disconnect between the drug's regulatory history and its modern clinical reality.

Investigational Uses and the COVID-19 Experience

Chloroquine's broad biological activities have led to its investigation for various other conditions, including viral infections like HIV and Zika virus.[1] Most prominently, the onset of the COVID-19 pandemic in early 2020 saw a surge of intense global interest in Chloroquine. Based on promising

in vitro data suggesting it could inhibit SARS-CoV-2 replication, the FDA issued an Emergency Use Authorization (EUA) on March 28, 2020, to allow its use in certain hospitalized patients.[38] However, subsequent large, randomized clinical trials failed to demonstrate any clinical benefit and, in some cases, suggested an increased risk of harm, particularly serious cardiac events.[39] Consequently, the FDA revoked the EUA on June 15, 2020, a decision echoed by warnings from the European Medicines Agency (EMA).[9] This episode serves as a powerful modern lesson on the importance of robust clinical evidence and the potential dangers of extrapolating preclinical findings directly to patient care.

The Global Challenge of Chloroquine Resistance

The decline of Chloroquine as a first-line antimalarial is a classic and sobering example of the impact of antimicrobial resistance on global public health.

Historical Emergence and Spread

The first documented cases of Chloroquine-resistant P. falciparum emerged nearly simultaneously but independently in two distinct geographic foci in the late 1950s: on the Thai-Cambodia border in Southeast Asia and in Colombia, South America.[8] From these origins, resistance spread inexorably throughout the 1960s and 1970s across Asia and South America. Sub-Saharan Africa, the region with the highest malaria burden, was spared until the late 1970s, when resistance was first detected in Kenya and Tanzania. Within a decade, it had swept across the continent.[6] More recently, resistance has also been reported in

P. vivax.[21]

Molecular Basis of Resistance

The primary molecular mechanism of Chloroquine resistance in P. falciparum has been definitively linked to mutations in a gene known as the P. falciparum chloroquine resistance transporter (pfcrt).[21] This gene encodes a protein located on the membrane of the parasite's digestive vacuole. The mutated PfCRT protein is thought to function as a transporter that actively pumps protonated Chloroquine out of the vacuole.[10] This efflux mechanism prevents the drug from accumulating to the high concentrations necessary to inhibit heme polymerization, allowing the parasite to survive and replicate despite the presence of the drug.

Impact on Global Malaria Control

The global spread of Chloroquine resistance had a devastating impact, leading to a dramatic resurgence in malaria-related illness and death, particularly among children in Africa.[21] It was a major contributing factor to the failure of the mid-20th century global malaria eradication campaign. This public health crisis forced a fundamental shift in global malaria treatment policy, moving away from inexpensive Chloroquine monotherapy to significantly more expensive but highly effective artemisinin-based combination therapies (ACTs).[1] The cost difference is stark: a course of Chloroquine costs approximately $0.10, whereas a course of ACTs can cost $1.00 to $2.40 or more.[61] This price differential represents a major and ongoing economic challenge for malaria control programs in low-income countries.

Comprehensive Safety Profile and Risk Management

While effective for its indications, Chloroquine has a significant and complex safety profile that requires careful patient selection, dosing, and monitoring to mitigate risks.

Common and Systemic Adverse Reactions

The most frequently reported adverse effects are generally mild and include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal cramps.[49] Headaches are also common.[49] A particularly notable side effect is pruritus (itching), which occurs with very high frequency in individuals of African descent.[63] Other systemic effects can include skin rashes, pigmentary changes of the skin and hair, and hair loss.[63] Neuropsychiatric effects, while less common, can be severe and may include confusion, anxiety, paranoia, hallucinations, and suicidal ideation.[50]

Major Toxicity Focus I: Chloroquine-Induced Retinopathy

The most feared long-term complication of Chloroquine therapy is irreversible retinopathy.

• Pathophysiology: This toxicity is characterized by progressive damage to the retinal pigment epithelium (RPE) and photoreceptors, particularly in the macula. In its classic advanced form, it creates a "bull's eye maculopathy" visible on fundoscopic examination.[68] The underlying mechanism is believed to be Chloroquine's high affinity for melanin, which leads to its accumulation to toxic levels within the RPE, causing lysosomal dysfunction and subsequent cellular damage.[42]
• Risk Factors: The risk of retinopathy is strongly dose- and duration-dependent. The most critical risk factors include a daily dose exceeding 2.3 mg/kg of actual body weight, a duration of use greater than five years, a high cumulative lifetime dose, underlying renal disease (which impairs drug clearance), concomitant use of tamoxifen, and pre-existing macular disease.[7]
• Screening and Management: Due to the irreversible nature of the damage, which can progress even after the drug is discontinued, diligent screening is mandatory for patients on long-term therapy.[69] Current guidelines recommend a baseline ophthalmological examination within the first year of starting Chloroquine, followed by annual screening beginning after five years of use (or sooner for high-risk patients). The recommended screening tests include spectral-domain optical coherence tomography (SD-OCT) and an automated visual field test of the central 10 degrees.[7] If any signs of toxicity are detected, the drug should be discontinued immediately.

Major Toxicity Focus II: Cardiotoxicity

Cardiac toxicity is another serious, potentially fatal complication associated with both chronic use and acute overdose.

• Manifestations: Chronic, high-dose therapy can lead to an infiltrative cardiomyopathy, characterized by conduction disorders (e.g., bundle branch block, atrioventricular block), myocardial hypertrophy, and restrictive heart failure, which can be fatal.[7] Acute overdose is a medical emergency that can cause severe hypotension, cardiovascular collapse, and life-threatening ventricular arrhythmias, including QT interval prolongation, torsades de pointes, and ventricular fibrillation.[1]
• Pathophysiology: The chronic cardiomyopathy is thought to result from lysosomal dysfunction within cardiomyocytes, similar to the process in the retina, leading to the accumulation of metabolic byproducts and causing cellular damage and fibrosis.[73] The acute arrhythmogenic effects are due to direct blockade of cardiac sodium and potassium ion channels.[42]

Contraindications, Warnings, and Precautions

• Contraindications: Chloroquine is contraindicated in patients with a known hypersensitivity to 4-aminoquinoline compounds. For indications other than acute malaria, it is also contraindicated in patients with pre-existing retinal or visual field changes.[16]
• Warnings: A critical warning concerns pediatric safety. Children are exceptionally sensitive to the toxic effects of Chloroquine, and accidental ingestion of as little as one or two tablets can be fatal. The medication must be kept securely out of the reach of children.[6]
• Precautions: Caution should be exercised when prescribing Chloroquine to patients with certain underlying conditions. These include hepatic or renal impairment (due to altered drug clearance), glucose-6-phosphate dehydrogenase (G6PD) deficiency (risk of hemolysis), psoriasis or porphyria (conditions may be exacerbated), and a history of epilepsy or cardiac disease.[51]

Due to its metabolism and effects on cardiac rhythm, Chloroquine is subject to numerous drug-drug interactions, as summarized in Table 3.

Table 3: Major Drug Interactions with Chloroquine

Interacting Drug/Class	Effect of Interaction	Clinical Management/Recommendation	Source(s)
Antacids, Kaolin	Decreased Chloroquine absorption	Separate administration by at least 4 hours	6
Cimetidine	Increased Chloroquine plasma levels (inhibits metabolism)	Concomitant use should be avoided	6
Ampicillin	Decreased ampicillin bioavailability	Separate administration by at least 2 hours	6
Cyclosporine	Increased cyclosporine serum levels	Monitor cyclosporine levels closely; may require Chloroquine discontinuation	6
Mefloquine	Increased risk of convulsions	Co-administration may increase seizure risk	6
QT-prolonging agents (e.g., amiodarone, moxifloxacin, azithromycin)	Increased risk of life-threatening ventricular arrhythmias	Use with extreme caution or avoid; ECG monitoring is required	51
CYP2D6 Substrates	Inhibition of CYP2D6 can increase levels of co-administered drugs	Use with caution; may require dose reduction of the CYP2D6 substrate	82

Dosage, Administration, and Patient Management

Accurate dosing of Chloroquine is paramount to ensure efficacy while minimizing the risk of toxicity. Dosages are often expressed in terms of the salt form (chloroquine phosphate) but should be calculated based on the equivalent amount of Chloroquine base.

Dosing Regimens for Malarial Indications

• Prophylaxis: For adults, the standard prophylactic dose is 500 mg of chloroquine phosphate (equivalent to 300 mg base) taken orally once per week. For children, the dose is 8.3 mg/kg of salt (5 mg/kg base) once weekly, not to exceed the adult dose. Therapy should begin 1-2 weeks before entering an endemic area and continue for 4 weeks after departure.[15]
• Treatment of Acute Attack: For adults, treatment consists of an initial oral dose of 1 g salt (600 mg base), followed by 500 mg salt (300 mg base) 6-8 hours later, and then 500 mg salt once daily on the following two days. The total dose is 2.5 g salt (1.5 g base) over three days. For children, the total dose is 25 mg/kg base, administered as an initial dose of 10 mg/kg base, followed by 5 mg/kg base at 6, 24, and 36 hours.[15]

Dosing Regimens for Rheumatic and Dermatologic Diseases

For conditions like RA and SLE, the goal is to use the lowest effective dose to control symptoms. A typical adult dose is 250 mg of chloroquine phosphate (150 mg base) daily.[85] However, to mitigate the risk of retinal toxicity, the daily dose should not exceed 2.3 mg/kg based on the patient's actual body weight. For many patients, this necessitates intermittent dosing (e.g., taking the medication only on certain days of the week) rather than daily administration.[14]

Considerations for Special Populations

• Pediatrics: Dosing must be calculated meticulously based on body weight, as children are highly susceptible to overdose, which can be fatal.[6] Long-term therapy in children is generally contraindicated.[65]
• Geriatrics: While no specific dose adjustments are mandated, caution is warranted as elderly patients are more likely to have reduced renal function, which can lead to drug accumulation and increased risk of toxicity.[51]
• Renal Impairment: Because Chloroquine is substantially cleared by the kidneys, dose reduction is required in patients with severe renal impairment. For patients with a glomerular filtration rate (GFR) of less than 10 mL/min, the dose should be reduced by 50%.[14]
• Hepatic Impairment: Chloroquine concentrates in the liver and should be used with caution in patients with hepatic disease or alcoholism, although specific dose adjustment guidelines are not established.[65]

Table 4: Summary of Dosage and Administration by Indication

Indication	Population	Dosage (as Base)	Duration/Notes	Source(s)
Malaria Prophylaxis	Adult	300 mg once weekly	Start 1-2 weeks pre-travel, continue 4 weeks post-travel	15
	Pediatric	5 mg/kg once weekly (max 300 mg)	Same as adult schedule	15
Malaria Treatment (Uncomplicated)	Adult	600 mg initial, then 300 mg at 6, 24, & 48 hrs	Total course over 3 days (1.5 g base total)	15
	Pediatric	10 mg/kg initial, then 5 mg/kg at 6, 24, & 36 hrs	Total course over 3 days (25 mg/kg base total)	15
Extraintestinal Amebiasis	Adult	600 mg daily for 2 days, then 300 mg daily	For at least 2-3 weeks, with an intestinal amebicide	16
Rheumatoid Arthritis / SLE	Adult	150 mg daily (or intermittent)	Long-term use. Do not exceed 2.3 mg/kg/day to minimize retinopathy risk.	14

Comparative Analysis and Therapeutic Positioning

Chloroquine's place in modern medicine is best understood by comparing it to its principal alternatives in both infectious disease and rheumatology.

Chloroquine versus Alternative Antimalarials

The decision to use Chloroquine for malaria prophylaxis is now highly dependent on geography due to resistance. Table 5 compares it with other common prophylactic agents. Chloroquine's main advantages are its extremely low cost and convenient weekly dosing schedule. However, its efficacy is limited to a few regions of the world. Atovaquone/proguanil and doxycycline are effective against resistant strains but are more expensive and require daily dosing. Mefloquine is also effective and dosed weekly but is associated with a significant risk of neuropsychiatric side effects.

Table 5: Comparative Analysis of Antimalarials for Prophylaxis

Agent	Efficacy vs. Resistant P. falciparum	Dosing Schedule	Cost (Relative)	Key Adverse Effects	Use in Pregnancy/Pediatrics
Chloroquine	None	Weekly	Very Low	Pruritus, GI upset, long-term retinopathy risk	Considered safe in pregnancy; weight-based dosing for children
Atovaquone/Proguanil	High	Daily	High	GI upset (generally well-tolerated)	Not recommended in pregnancy; pediatric formulation available
Doxycycline	High	Daily	Low	Photosensitivity, GI upset, vaginal candidiasis	Contraindicated in pregnancy and children <8 years
Mefloquine	High	Weekly	Moderate	Neuropsychiatric effects (vivid dreams, anxiety, psychosis), dizziness	May be used in 2nd/3rd trimesters; use with caution in children

Chloroquine versus Other Disease-Modifying Antirheumatic Drugs (DMARDs)

In rheumatology, Chloroquine (and more commonly, hydroxychloroquine) is considered a "milder" conventional synthetic DMARD (csDMARD). Table 6 compares it to other common DMARDs for rheumatoid arthritis. Methotrexate is the undisputed first-line "anchor" drug for moderate-to-severe RA due to its superior efficacy in preventing joint damage. Chloroquine is often used for milder disease or in combination with other DMARDs. Its favorable safety profile regarding myelosuppression and hepatotoxicity (compared to methotrexate) and its relative safety in pregnancy are key advantages. However, the unique and serious risks of long-term retinopathy and cardiotoxicity require diligent monitoring, and its efficacy is less robust than that of methotrexate or biologic agents.

Table 6: Comparative Analysis of Chloroquine with Other DMARDs for RA

Agent	Relative Efficacy	Onset of Action	Primary Long-Term Toxicities	Monitoring Requirements	Cost (Relative)	Use in Pregnancy
Chloroquine/HCQ	Mild to Moderate	Slow (2-6 months)	Retinopathy, Cardiomyopathy	Annual ophthalmology exams	Low	Generally considered safe
Methotrexate	High	Intermediate (1-2 months)	Hepatotoxicity, Myelosuppression, Pulmonary fibrosis	Frequent blood tests (liver, CBC)	Low	Contraindicated (teratogenic)
Sulfasalazine	Moderate	Intermediate (1-3 months)	GI upset, Rash, Myelosuppression	Frequent blood tests (liver, CBC)	Low	Generally considered safe
Biologics (TNF inhibitors)	Very High	Rapid (weeks)	Serious infections, Malignancy risk	Tuberculosis screening, infection monitoring	Very High	Varies by agent

Conclusion: The Enduring and Complex Legacy of Chloroquine

Chloroquine holds a unique and paradoxical position in the history of modern medicine. It is a drug that rose from a wartime imperative to become a pillar of global public health, fundamentally altering the fight against malaria. Its journey encapsulates the power of synthetic chemistry to improve upon nature, the critical role of serendipity in discovering new therapeutic applications, and the sobering reality of microbial evolution in the face of selective pressure.

The spread of resistance has largely relegated Chloroquine from its primary role as a first-line antimalarial to a niche agent for use in the few remaining areas of susceptibility. Simultaneously, its second life as a cornerstone therapy for systemic lupus erythematosus and a useful agent in rheumatoid arthritis has ensured its continued clinical relevance. This dual identity is governed by a single, elegant pharmacological principle—lysosomotropism—which is both the source of its efficacy and the root of its most dangerous toxicities. The very pharmacokinetic properties of extensive tissue accumulation and slow elimination that make it a convenient weekly prophylactic create the preconditions for irreversible retinal and cardiac damage with chronic use.

The recent intense but failed investigation into its use for COVID-19 provided a stark, public lesson on the gap between in vitro plausibility and in vivo reality, reinforcing the primacy of rigorous clinical evidence. Ultimately, Chloroquine's legacy is one of complexity. It is a powerful, inexpensive, and historically transformative medication whose study offers enduring lessons in pharmacology, infectious disease, and immunology. It remains a valuable tool in the therapeutic arsenal, but one that demands a profound respect for its intricate benefit-risk profile and a commitment to careful, evidence-based patient management.

Works cited

1. Chloroquine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 2, 2025, https://go.drugbank.com/drugs/DB00608
2. Chloroquine | C18H26ClN3 | CID 2719 - PubChem, accessed August 2, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/2719
3. CAS 54-05-7 Chloroquine - BOC Sciences, accessed August 2, 2025, https://www.bocsci.com/product/chloroquine-cas-54-05-7-12358.html
4. chloroquine | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed August 2, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5535
5. Pharmacology of Chloroquine and Hydroxychloroquine - PMC - PubMed Central, accessed August 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7122276/
6. Chloroquine - Wikipedia, accessed August 2, 2025, https://en.wikipedia.org/wiki/Chloroquine
7. Chloroquine Phosphate Tablets - accessdata.fda.gov, accessed August 2, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/090610Orig1s004,s005lbl.pdf
8. chloroquine | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed August 2, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=malaria&ligandId=5535
9. Chloroquine hydrochloride | DrugBank Online, accessed August 2, 2025, https://go.drugbank.com/salts/DBSALT001317
10. The host targeting effect of chloroquine in malaria - PMC - PubMed Central, accessed August 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7431399/
11. Hydroxychloroquine as an important immunomodulator: a novel insight into an old drug, accessed August 2, 2025, https://www.mp.pl/paim/issue/article/16656/
12. Hydroxychloroquine in rheumatic autoimmune disorders and beyond - EMBO Press, accessed August 2, 2025, https://www.embopress.org/doi/10.15252/emmm.202012476
13. Chloroquine - eEML - Electronic Essential Medicines List, accessed August 2, 2025, https://list.essentialmeds.org/medicines/275
14. Chloroquine - DermNet, accessed August 2, 2025, https://dermnetnz.org/topics/chloroquine
15. Chloroquine Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed August 2, 2025, https://www.drugs.com/dosage/chloroquine.html
16. Chloroquine Phosphate Tablets West-ward - accessdata.fda.gov, accessed August 2, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/083082s050lbl.pdf
17. Insights in Chloroquine Action: Perspectives and Implications in Malaria and COVID‐19, accessed August 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7404934/
18. Hydroxychloroquine history and its cardiovascular safety - FPM, accessed August 2, 2025, https://www.fpm.org.uk/blog/hydroxychloroquine-history-and-its-cardiovascular-safety/
19. PITFALLS IN A DISCOVERY: THE CHRONICLE OF CHLOROQUINE* G. ROBERT COATNEY It is traditional in this Society that the Presi dent d - ASTMH, accessed August 2, 2025, https://www.astmh.org/ASTMH/media/Documents/Presidential%20Addresses/1962-G-Robert-Coatney.pdf
20. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases - Oxford Academic, accessed August 2, 2025, https://academic.oup.com/jac/article/70/6/1608/728687
21. Chloroquine-Resistant Malaria | The Journal of Infectious Diseases | Oxford Academic, accessed August 2, 2025, https://academic.oup.com/jid/article/184/6/770/846627
22. History of antimalarial drugs - Medicines for Malaria Venture, accessed August 2, 2025, https://www.mmv.org/malaria-medicines/history-antimalarials-drugs
23. Hydroxychloroquine: An old drug with new relevance | Cleveland Clinic Journal of Medicine, accessed August 2, 2025, https://www.ccjm.org/content/85/6/459
24. Understanding Lupus, the Disease Treated by Chloroquine and Hydroxychloroquine, accessed August 2, 2025, https://sph.umich.edu/pursuit/2020posts/understanding-lupus-the-disease-treated-by-chloroquine-and-hydroxychloroquine.html
25. Hydroxychloroquine | C18H26ClN3O | CID 3652 - PubChem, accessed August 2, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Hydroxychloroquine
26. go.drugbank.com, accessed August 2, 2025, https://go.drugbank.com/drugs/DB00608#:~:text=Chloroquine%20inhibits%20the%20action%20of%20heme%20polymerase%20in%20malarial%20trophozoites,conversion%20of%20heme%20to%20hemazoin.&text=Plasmodium%20species%20continue%20to%20accumulate%20toxic%20heme%2C%20killing%20the%20parasite.
27. On the molecular mechanism of chloroquine's antimalarial action. - PNAS, accessed August 2, 2025, https://www.pnas.org/doi/10.1073/pnas.93.21.11865
28. Full article: Antimalarial Drug Resistance: A Brief History of Its Spread in Indonesia, accessed August 2, 2025, https://www.tandfonline.com/doi/full/10.2147/DDDT.S403672
29. Mechanism of action of hydroxychloroquine as an antirheumatic drug - PubMed, accessed August 2, 2025, https://pubmed.ncbi.nlm.nih.gov/8278823/
30. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology, accessed August 2, 2025, http://sdpomf.com/ficheros/web/noticias/3b0aa45e04b3ae02ce7abc4db6abeff0e3b921878b0b38010d76a65548d652c6.pdf
31. Chloroquine and hydroxychloroquine: Immunomodulatory effects in autoimmune diseases - Baishideng Publishing Group, accessed August 2, 2025, https://www.wjgnet.com/1949-8454/full/v16/i2/107042.htm
32. Hydroxychloroquine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 2, 2025, https://go.drugbank.com/drugs/DB01611
33. (PDF) Immunomodulatory Effects of Hydroxychloroquine and Chloroquine in Viral Infections and Their Potential Application in Retinal Gene Therapy - ResearchGate, accessed August 2, 2025, https://www.researchgate.net/publication/342926252_Immunomodulatory_Effects_of_Hydroxychloroquine_and_Chloroquine_in_Viral_Infections_and_Their_Potential_Application_in_Retinal_Gene_Therapy
34. Immunomodulatory Effects of Chloroquine/Hydroxychloroquine - Frontiers, accessed August 2, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.01409/epub
35. Chloroquine and hydroxychloroquine: Immunomodulatory effects in autoimmune diseases - Baishideng Publishing Group, accessed August 2, 2025, https://www.wjgnet.com/1949-8454/full/v16/i2/107042-g001.htm
36. Mechanisms Underlying the Effects of Chloroquine on Red Blood Cells Metabolism - MDPI, accessed August 2, 2025, https://www.mdpi.com/1422-0067/25/12/6424
37. Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19 - PubMed Central, accessed August 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7655531/
38. Chloroquine phosphate EUA fact sheet for healthcare providers - FDA, accessed August 2, 2025, https://www.fda.gov/media/136535/download
39. Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine, accessed August 2, 2025, https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and
40. kinetics of chloroquine and desethylchloroquine - IRIS, accessed August 2, 2025, https://iris.who.int/bitstream/handle/10665/264320/PMC2490847.pdf?sequence=1&isAllowed=y
41. Volume of Distribution, accessed August 2, 2025, https://clinpharmacol.fmhs.auckland.ac.nz/docs/volume-of-distribution-sj.pdf
42. Chloroquine and Hydroxychloroquine Toxicity - StatPearls - NCBI Bookshelf, accessed August 2, 2025, https://www.ncbi.nlm.nih.gov/books/NBK537086/
43. Characterization of chloroquine plasma protein binding in man. | DrugBank Online, accessed August 2, 2025, https://go.drugbank.com/articles/A191673
44. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements, accessed August 2, 2025, https://pubmed.ncbi.nlm.nih.gov/8896943/
45. Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. - DrugBank, accessed August 2, 2025, https://go.drugbank.com/articles/A38847
46. Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters - PMC, accessed August 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8717092/
47. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation - PubMed, accessed August 2, 2025, https://pubmed.ncbi.nlm.nih.gov/12756207/
48. Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters - ResearchGate, accessed August 2, 2025, https://www.researchgate.net/publication/347479789_Metabolism_and_Interactions_of_Chloroquine_and_Hydroxychloroquine_with_Human_Cytochrome_P450_Enzymes_and_Drug_Transporters
49. Medicines for the Prevention of Malaria While Traveling - Chloroquine (Aralen™) - CDC, accessed August 2, 2025, https://www.cdc.gov/malaria/resources/pdf/fsp/drugs_2017/Chloroquine_2017.pdf
50. Chloroquine - StatPearls - NCBI Bookshelf, accessed August 2, 2025, https://www.ncbi.nlm.nih.gov/books/NBK551512/
51. Chloroquine (oral route) - Side effects & dosage - Mayo Clinic, accessed August 2, 2025, https://www.mayoclinic.org/drugs-supplements/chloroquine-oral-route/description/drg-20062834
52. Treating Lupus with Anti-Malarial Drugs, accessed August 2, 2025, https://www.hopkinslupus.org/lupus-treatment/lupus-medications/antimalarial-drugs/
53. Hydroxychloroquine in SLE: old drug, new perspectives - PMC, accessed August 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7097534/
54. Off-label and/or Investigational Drugs Used to Treat COVID 19 and/or Related Conditions (Including addendum for use of hydroxych - DHCS, accessed August 2, 2025, https://www.dhcs.ca.gov/Documents/COVID-19/COVID-19-Drug-Policy-040220-HC-Add.pdf
55. FDA issues advisory on off-label use of hydroxychloroquine and chloroquine, accessed August 2, 2025, https://cancerletter.com/covid-19-updates/20200424_8/
56. Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel - PubMed, accessed August 2, 2025, https://pubmed.ncbi.nlm.nih.gov/33345848/
57. COVID-19: reminder of the risks of chloroquine and hydroxychloroquine | European Medicines Agency (EMA), accessed August 2, 2025, https://www.ema.europa.eu/en/news/covid-19-reminder-risks-chloroquine-and-hydroxychloroquine
58. On the Mechanism of Chloroquine Resistance in Plasmodium falciparum | PLOS One, accessed August 2, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0014064
59. Malaria - World Health Organization (WHO), accessed August 2, 2025, https://www.who.int/news-room/fact-sheets/detail/malaria
60. Malaria - Diagnosis & treatment - Mayo Clinic, accessed August 2, 2025, https://www.mayoclinic.org/diseases-conditions/malaria/diagnosis-treatment/drc-20351190
61. The Cost and Cost-Effectiveness of Antimalarial Drugs - Saving Lives, Buying Time - NCBI, accessed August 2, 2025, https://www.ncbi.nlm.nih.gov/books/NBK215621/
62. Chloroquine (Aralen): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing, accessed August 2, 2025, https://www.webmd.com/drugs/2/drug-8633/chloroquine-oral/details
63. Chloroquine Side Effects: Common, Severe, Long Term - Drugs.com, accessed August 2, 2025, https://www.drugs.com/sfx/chloroquine-side-effects.html
64. Review of side effects and toxicity of chloroquine - World Health Organization (WHO), accessed August 2, 2025, https://apps.who.int/iris/bitstream/handle/10665/65773/WHO_MAL_79.906.pdf
65. Chloroquine - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Renal Dose, Hepatic Dose | Drug Index | Pediatric Oncall, accessed August 2, 2025, https://www.pediatriconcall.com/drugs/chloroquine/404
66. Chloroquine and Hydroxychloroquine: Risk of Psychiatric Disorders - NPRA, accessed August 2, 2025, https://www.npra.gov.my/index.php/en/component/content/article/444-english/safety-alerts-main/safety-alerts-2022/1527380-chloroquine-and-hydroxychloroquine-risk-of-psychiatric-disorders.html?Itemid=1391
67. Other safety alerts - 2020-11-28 (1), accessed August 2, 2025, https://www.drugoffice.gov.hk/eps/news/showNews/newsTitle/healthcare_providers/2020-11-28/en/42349.html
68. en.wikipedia.org, accessed August 2, 2025, https://en.wikipedia.org/wiki/Chloroquine_retinopathy#:~:text=Chloroquine%20retinopathy%20is%20a%20form,arthritis%20and%20systemic%20lupus%20erythematosus.
69. Chloroquine retinopathy - Wikipedia, accessed August 2, 2025, https://en.wikipedia.org/wiki/Chloroquine_retinopathy
70. Retinal Damage in Chloroquine Maculopathy, Revealed by High Resolution Imaging: A Case Report Utilizing Adaptive Optics Scanning Laser Ophthalmoscopy - PMC, accessed August 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3913974/
71. Hydroxychloroquine and Chloroquine Retinopathy: Recommendations on Monitoring - The Royal College of Ophthalmologists |, accessed August 2, 2025, https://www.rcophth.ac.uk/wp-content/uploads/2020/12/Hydroxychloroquine-and-Chloroquine-Retinopathy-Monitoring-Guideline.pdf
72. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy - 2016 - American Academy of Ophthalmology, accessed August 2, 2025, https://www.aao.org/education/clinical-statement/revised-recommendations-on-screening-chloroquine-h
73. Chloroquine and hydroxychloroquine induced cardiomyopathy: A systematic review of literature | REC: CardioClinics, accessed August 2, 2025, https://www.reccardioclinics.org/en-chloroquine-and-hydroxychloroquine-induc-articulo-S2605153225000329
74. Antimalarial-Mediated Cardiotoxicity: Evaluation and Preliminary Screening Recommendations For Patients on Chronic Therapy for Autoimmune Rheumatic Diseases - American College of Cardiology, accessed August 2, 2025, https://www.acc.org/Latest-in-Cardiology/Articles/2025/02/14/16/19/Antimalarial-Mediated-Cardiotoxicity
75. Cardiac toxicity secondary to long term treatment with chloroquine | Annals of the Rheumatic Diseases, accessed August 2, 2025, https://ard.bmj.com/content/60/3/301
76. A Case Report and Review of the Literature Cardiac Damage from Chronic Use of Chloroquine - SciELO, accessed August 2, 2025, https://www.scielo.br/j/abc/a/vcHb4cGwd5yvvBTTLLRnP3c/
77. FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems, accessed August 2, 2025, https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or
78. Chloroquine Cardiotoxicity Leading to Cardiogenic Shock | JACC: Case Reports, accessed August 2, 2025, https://www.jacc.org/doi/10.1016/j.jaccas.2020.09.044
79. Cardiac effects and toxicity of chloroquine: a short update - PMC - PubMed Central, accessed August 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7303034/
80. Chloroquine: Package Insert / Prescribing Information - Drugs.com, accessed August 2, 2025, https://www.drugs.com/pro/chloroquine.html
81. Chloroquine: Pediatric Medication | Memorial Sloan Kettering Cancer Center, accessed August 2, 2025, https://www.mskcc.org/cancer-care/patient-education/medications/pediatric/chloroquine
82. Chloroquine phosphate (chloroquine) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed August 2, 2025, https://reference.medscape.com/drug/chloroquine-phosphate-chloroquine-342687
83. www.mayoclinic.org, accessed August 2, 2025, https://www.mayoclinic.org/drugs-supplements/chloroquine-oral-route/description/drg-20062834#:~:text=If%20you%20are%20also%20taking,or%20after%20using%20this%20medicine.
84. Malaria in the United States: Treatment Tables | CDC, accessed August 2, 2025, https://www.cdc.gov/malaria/resources/pdf/Malaria_Treatment_Table_202306.pdf
85. Chloroquine (Aralen) | Davis's Drug Guide - Nursing Central, accessed August 2, 2025, https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/51147/all/chloroquine
86. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus - PubMed, accessed August 2, 2025, https://pubmed.ncbi.nlm.nih.gov/8803897/
87. Chloroquine Advanced Patient Information - Drugs.com, accessed August 2, 2025, https://www.drugs.com/cons/chloroquine.html
88. Pharmaceutical care of chloroquine phosphate in elderly patients with coronavirus pneumonia (COVID‐19) - PMC, accessed August 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7338693/
89. The risk of antimalarials in patients with renal failure - PMC, accessed August 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2750932/
90. Chloroquine - LiverTox - NCBI Bookshelf, accessed August 2, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548224/